Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 10/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26239251 | 0.88 | KCNH2 (0.57) | KCNH2MAPTCRHBPCRHR2MAOB | |
| SCHEMBL26239231 | 0.83 | PPARG (0.44) | L3MBTL1 | |
| SCHEMBL9763578 | 0.78 | GAA (0.43) | MAPTGAA | |
| SCHEMBL29575512 | 0.77 | LMNA (0.45) | KCNH2MAPTGAA | |
| SCHEMBL26239235 | 0.77 | ALDH1A1 (0.54) | KCNH2MAPTCRHBPCRHR2L3MBTL1 | |
| SCHEMBL29576677 | 0.76 | LMNA (0.44) | KCNH2MAPTGAA | |
| SCHEMBL26239239 | 0.75 | KCNH2 (0.54) | KCNH2ACHE | |
| SCHEMBL7281801 | 0.75 | MEN1 (0.52) | MAPTCRHBPCRHR2 | |
| SCHEMBL2478557 | 0.75 | KCNH2 (0.60) | KCNH2MAPTACHEGAA | |
| SCHEMBL2234342 | 0.73 | PTPRB (0.52) | MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025846-A1 | ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS | ACAD PHARMACEUTICALS INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11731938-B2 | Ultra short acting anti-arrhythmic agents | ACADEMIC PHARMACEUTICALS INC (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731938-B2 | Ultra short acting anti-arrhythmic agents | CACNA1G, SCN5A, CACNA1F | KCNH2 51/4885MAPT 3515/4885CRHBP 3730/4885 |
| US-20240025846-A1 | ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS | CACNA1G, SCN5A, CACNA1F | KCNH2 51/4885MAPT 3515/4885CRHBP 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.